Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Circulatory Shock
Interventions
DRUG

Initiation of vasopressine as a first vasoconstrictive drug

The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.

DRUG

Initiation of noradrenaline as a first vasoconstrictive drug

ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.

Trial Locations (1)

41110

RECRUITING

General University Hospital of Larissa, Intensive Care Unit, Larissa

All Listed Sponsors
lead

University of Thessaly

OTHER